Metabolic Disorders
Beta Bionics’ automated insulin delivery system picks up manufacturing partner
Chronic disease tech company Convatec Group has partnered with Beta Bionics to manufacture the insulin delivery system iLet Bionic Pancrease.…
Amicus’ Opfolda wins positive CHMP opinion in Pompe Disease
Amicus Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Opfolda…
Hasten Biopharmaceutic raises $315m for pipeline assets development
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by…
Madrigal wins FDA fast track designation for NASH drug
The FDA has granted Madrigal Pharmaceuticals’ resmetirom a Fast Track designation for nonalcoholic steatohepatitis (NASH) with liver fibrosis, as the…
Insulin pricing in flux as major pharma players take action
As the three main US pharmaceutical insulin suppliers, Novo Nordisk, Sanofi and Eli Lilly, have announced major price reductions, and…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Viking’s weight loss drug enters an already crowded arena
Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1)…
Eli Lilly places price cap of $35 on out-of-pocket insulin cost
Eli Lilly has announced that it will reduce the price of its most commonly used insulin, Humalog, in the US,…
Sosei Heptares and Lilly enter partnership for small molecules development
Sosei Heptares and Eli Lilly and Company have signed a partnership for the discovery, development and commercialisation of small molecules that modulate new G protein-coupled…
UK Government to fund research into new obesity treatments
The UK Government has announced funds worth $24.17m (£20m) to conduct research for developing new obesity therapies and technologies. These therapies and…
Novo Nordisk submitting once-weekly insulin to FDA following Phase III success
Novo Nordisk has recently completed its six-part ONWARDS Phase III trial, as ONWARDS 5 reached its primary endpoint with Icodec…